[go: up one dir, main page]

AR057180A1 - Formulacion farmaceutica de absorcion oral que comprende insulina, entre otros, y su metodo de administracion - Google Patents

Formulacion farmaceutica de absorcion oral que comprende insulina, entre otros, y su metodo de administracion

Info

Publication number
AR057180A1
AR057180A1 ARP060105216A ARP060105216A AR057180A1 AR 057180 A1 AR057180 A1 AR 057180A1 AR P060105216 A ARP060105216 A AR P060105216A AR P060105216 A ARP060105216 A AR P060105216A AR 057180 A1 AR057180 A1 AR 057180A1
Authority
AR
Argentina
Prior art keywords
micelle
insulin
pharmaceutical formulation
administration
formulation
Prior art date
Application number
ARP060105216A
Other languages
English (en)
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Publication of AR057180A1 publication Critical patent/AR057180A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulacion farmacéutica para absorber por la mucosa oral que incluye una cantidad efectiva de (a) un agente farmacéutico en forma de micela combinada como por ejemplo insulina, entre otros; (b) al menos un compuesto formador de micela seleccionado del grupo de sulfato alquilo de metal alcalino y monooleato de sorbitan polioxietileno; (c) un copolímero bloque de polioxietileno y polioxipropileno; (d) al menos un compuesto formador de micela adicional y (e) un disolvente adecuado. Proporciona además un dispensador de dosis graduado (aerosol y no aerosol) que contiene la presente formulacion y un método de administracion de insulina con un dispensador de dosis graduado que incluye administrar dosis multiples de una formulacion que contiene insulina antes y después de cada comida.
ARP060105216A 2005-11-30 2006-11-27 Formulacion farmaceutica de absorcion oral que comprende insulina, entre otros, y su metodo de administracion AR057180A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2005/001816 WO2007062494A1 (en) 2005-11-30 2005-11-30 Orally absorbed pharmaceutical formulation and method of administration

Publications (1)

Publication Number Publication Date
AR057180A1 true AR057180A1 (es) 2007-11-21

Family

ID=38091821

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105216A AR057180A1 (es) 2005-11-30 2006-11-27 Formulacion farmaceutica de absorcion oral que comprende insulina, entre otros, y su metodo de administracion

Country Status (15)

Country Link
US (2) US20090214657A1 (es)
EP (1) EP1954242A4 (es)
JP (1) JP2009517410A (es)
CN (1) CN101309668A (es)
AP (1) AP2008004447A0 (es)
AR (1) AR057180A1 (es)
AU (1) AU2005338631B2 (es)
BR (1) BRPI0520704A2 (es)
CA (1) CA2630578C (es)
EA (1) EA200800979A1 (es)
EC (1) ECSP088403A (es)
IL (1) IL191531A0 (es)
NZ (1) NZ567601A (es)
UY (1) UY29905A1 (es)
WO (1) WO2007062494A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015456A1 (en) * 2007-07-30 2009-02-05 Generex Pharmaceuticals Inc. Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
CN101422431B (zh) * 2007-12-28 2011-03-23 上海医药工业研究院 胰岛素经鼻给药制剂
HUE048608T2 (hu) 2008-10-17 2020-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
CN100594929C (zh) * 2009-06-24 2010-03-24 薛南荣 口服胰岛素药物及其制备方法
RU2537239C2 (ru) 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
LT2498801T (lt) 2009-11-13 2018-05-10 Sanofi-Aventis Deutschland Gmbh Farmacinė kompozicija, apimanti despro36eksendin-4(1-39)-lys6-nh2 ir metioniną
CN102753150A (zh) * 2010-01-12 2012-10-24 诺沃—诺迪斯克有限公司 用于口服给予胰岛素肽的药物组合物
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
USD645954S1 (en) * 2010-05-21 2011-09-27 Consort Medical Plc Mechanical dosage counter apparatus
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102228680B (zh) * 2011-06-14 2013-02-27 中国人民解放军第三0二医院 胸腺肽的磷脂/胆盐复合胶束及其制备方法和制剂
WO2013003491A1 (en) * 2011-06-27 2013-01-03 Board Of Regents, The University Of Texas System Toroidal pharmaceutical formulations
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
SG11201506888VA (en) 2013-04-03 2015-09-29 Sanofi Sa Treatment of diabetes mellitus by long-acting formulations of insulins
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
FI3229828T3 (fi) 2014-12-12 2023-05-29 Sanofi Aventis Deutschland Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AU2016335287A1 (en) 2015-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
US11166912B2 (en) 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form
US12108809B1 (en) 2022-04-15 2024-10-08 Air 2, LLC Aerosol pressurized delivery device and methods for manufacture and use of the same
WO2024238520A1 (en) * 2023-05-15 2024-11-21 Air 2 LLC Pressurized sublingual delivery device and methods for manufacture and use of the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
DK0619730T3 (da) * 1992-10-08 2001-01-29 Supratek Pharma Inc Sammensætninger af antineoplastiske midler inkorporeret i miceller
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
IL122084A (en) * 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
US6063762A (en) * 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6451286B1 (en) * 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US6436367B1 (en) * 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6375975B1 (en) * 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6312665B1 (en) * 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
CA2375914A1 (en) * 1999-06-04 2000-12-14 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same

Also Published As

Publication number Publication date
IL191531A0 (en) 2008-12-29
EP1954242A4 (en) 2012-08-01
US20120171259A1 (en) 2012-07-05
UY29905A1 (es) 2007-05-31
CA2630578A1 (en) 2007-06-07
AP2008004447A0 (en) 2008-04-30
EA200800979A1 (ru) 2008-10-30
NZ567601A (en) 2010-12-24
ECSP088403A (es) 2008-05-30
CA2630578C (en) 2014-04-15
JP2009517410A (ja) 2009-04-30
WO2007062494A1 (en) 2007-06-07
CN101309668A (zh) 2008-11-19
AU2005338631A1 (en) 2007-06-07
EP1954242A1 (en) 2008-08-13
AU2005338631B2 (en) 2011-12-01
US20090214657A1 (en) 2009-08-27
BRPI0520704A2 (pt) 2009-05-19

Similar Documents

Publication Publication Date Title
AR057180A1 (es) Formulacion farmaceutica de absorcion oral que comprende insulina, entre otros, y su metodo de administracion
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
ES2169087T3 (es) Formulaciones orales de un antifungico.
DK1257254T3 (da) Formuleringer indeholdende et anticholinergt lægemiddel til behandling af kronisk obstruktiv lungesygdom
PE20080765A1 (es) Formas de dosificacion farmaceutica
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
ES2184310T3 (es) Formulacion autoemulsionante para compuestos lipofilos acidos.
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
FR2878161B1 (fr) Forme medicamenteuse orale, solide et concue pour eviter le mesusage
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
TN2009000504A1 (en) Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
CY1118461T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν αναστολεα αρωματασης
SG149054A1 (en) Multiparticulate formulations for oral delivery
GT200600261A (es) Formulaciones de diclofenac y metodos para usarlas
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
WO2013104892A8 (en) Application of high dose compounds via inhalation
DE60329968D1 (de) Dosierungsformen enthaltend Thyroidhormone und deren Herstellungsverfahren
TNSN07289A1 (en) Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
WO2007047371A3 (en) Pharmaceutical packaging of an oral dosage combination
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
MX2016014604A (es) Dispositivo de aerosol.
AR057745A1 (es) Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol
CR9941A (es) Formacion farmaceutica de absorcion oral y su metodo de administracion
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.

Legal Events

Date Code Title Description
FB Suspension of granting procedure